A Pilot Human Evaluation of a Formulation of Irinotecan and Hyaluronic Acid in 5-Fluorouracil-Refractory Metastatic Colorectal Cancer Patients

Publisher： Karger

E-ISSN： 1421-9794|55|1|49-59

ISSN： 0009-3157

Source： Chemotherapy, Vol.55, Iss.1, 2008-12, pp. : 49-59

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of a 48-Hour Infusion of 5-Fluorouracil without Folinic Acid with 24-Hour Folinic Acid/5-Fluorouracil in Patients with Metastatic Colorectal Cancer Refractory to Bolus Folinic Acid/5-Fluorouracil

By  

Chemotherapy, Vol. 49, Iss. 1-2, 2003-05 ,pp. : 85-89

Karger

Access to resources Recommend Favorite

Phase I and Pharmacokinetic Evaluation of Intravenous Hyaluronic Acid in Combination with Doxorubicin or 5-Fluorouracil

By  

Chemotherapy, Vol. 51, Iss. 2-3, 2005-06 ,pp. : 132-141

Karger

Access to resources Recommend Favorite

Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

By  

Chemotherapy, Vol. 56, Iss. 2, 2010-04 ,pp. : 142-146

Karger

Access to resources Recommend Favorite

Irinotecan-Cetuximab-Bevacizumab as a Salvage Treatment in Heavily Pretreated Metastatic Colorectal Cancer Patients: A Retrospective Observational Study

By  

Chemotherapy, Vol. 57, Iss. 2, 2011-03 ,pp. : 138-144

Karger

Access to resources Recommend Favorite

HLA-G 3′UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer

By Garziera Marica   Virdone Saverio   De Mattia Elena   Scarabel Lucia   Cecchin Erika   Polesel Jerry   D’Andrea Mario   Pella Nicoletta   Buonadonna Angela   Favaretto Adolfo   Toffoli Giuseppe  

International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-06 ,pp. : 1366-1366

MDPI

Access to resources Recommend Favorite